Non-alcoholic fatty liver disease: relationship with cardiovascular risk markers and clinical endpoints by Buckley, A. et al.
Accepted Manuscript
Review
Non-alcoholic fatty liver disease: relationship with cardiovascular risk markers
and clinical endpoints
Adam Buckley, E. Louise Thomas, Nader Lessan, Francesca M. Trovato,




To appear in: Diabetes Research and Clinical Practice
Received Date: 18 June 2018
Revised Date: 8 August 2018
Accepted Date: 14 August 2018
Please cite this article as: A. Buckley, E. Louise Thomas, N. Lessan, F.M. Trovato, G.M. Trovato, S.D. Taylor-
Robinson, Non-alcoholic fatty liver disease: relationship with cardiovascular risk markers and clinical endpoints,
Diabetes Research and Clinical Practice (2018), doi: https://doi.org/10.1016/j.diabres.2018.08.011
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process




Non-alcoholic fatty liver disease: relationship with cardiovascular risk markers and 
clinical endpoints  
Adam Buckley
1, 2

















1 Imperial College London, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine 
(London, United Kingdom);  
2 Imperial College London Diabetes Centre, Research Department (Abu Dhabi, United Arab Emirates);  
3 University of Westminster, Department of Life Sciences (London, United Kingdom); 
4 University of Catania, Department of Clinical and Experimental Medicine (Catania, Italy)  
5 University of Catania, Department of Clinical and Experimental Medicine (Catania, Italy) 
6 Imperial College London, Division of Integrative Systems Medicine and Digestive Health, Department of Surgery 
and Cancer (London, United Kingdom) 
 
Adam J Buckley - a.buckley13@imperial.ac.uk 
Elizabeth Louise Thomas - L.Thomas3@westminster.ac.uk 
Francesca M. Trovato - trovatofrancesca@gmail.com 
Guglielmo M. Trovato - trovato.eu@gmail.com 
Simon D. Taylor-Robinson - s.taylor-robinson@imperial.ac.uk 
 
Nader Lessan MD, FRCP (Corresponding Author) 
Consultant Endocrinologist  
Imperial College London Diabetes Centre 
PO Box 48338 
Abu Dhabi, United Arab Emirates 
Telephone:    009712 4040800, Ext 928  
Fax:               009712 4040900 







Non-alcoholic fatty liver disease (NAFLD) is a common diagnosis and is increasing in 
prevalence worldwide. NAFLD is usually asymptomatic at presentation; progression of the 
disease is unpredictable, leading to the development of a variety of techniques for screening, 
diagnosis and risk stratification. Clinical methods in current use include serum biomarker panels, 
hepatic ultrasound, magnetic resonance imaging, and liver biopsy.  
A NAFLD is strongly associated with the metabolic syndrome, and the most common cause of 
death for people with the condition is cardiovascular disease.  Whether NAFLD is an 
independent cardiovascular risk factor needs exploration. NAFLD has been associated with 
surrogate markers of cardiovascular disease such as carotid intima-media thickness, the presence 
of carotid plaque, brachial artery vasodilatory responsiveness and CT coronary artery 
calcification score.   
There is no effective medical treatment for NAFLD and evidence is lacking regarding the 
efficacy of interventions in mitigating cardiovascular risk. Health care professionals managing 
patients with NAFLD should tackle the issue with early identification of risk factors and 
aggressive modification. Current management strategies therefore comprise lifestyle change, 
with close attention to known cardiovascular risk factors. 
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Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are common 
conditions and are both associated with increased insulin resistance and vascular disease. The 
coexistence of diabetes mellitus and NAFLD increases the risk both of developing more severe 
forms of NAFLD and also of the evolution of chronic vascular complications of diabetes mellitus 
[1]. NAFLD is characterized by the accumulation of liver fat in the absence of excessive alcohol 
intake.  The liver has a vital role in systemic metabolism, contributing significantly to the 
development of insulin resistance and type 2 diabetes mellitus (T2DM) [2]. Hepatic insulin 
signaling is essential to maintain the carbohydrate and lipid homeostasis [3]. Cytokines, 
adipocytokines and lipotoxins have been postulated to play a crucial part in the pathogenesis of 
both T2DM and NAFLD [2]. Clinically relevant fibrosis affects up to 20% of individuals with 
both diagnoses [4]. Non-alcoholic steatohepatitis (NASH), which is distinguished from simple 
steatosis by the presence of progressive hepatocyte injury and fibrosis, is increasingly common 
as a primary or secondary indication for liver transplantation, as decompensated cirrhosis is the 
end result of the progressive condition [5]. As a consequence, the combination of both T2DM 
and NAFLD is of increasing clinical concern, as a potential cause of both the exacerbation of 
liver injury and the potential risk of cardiovascular disease. 
 
Epidemiology 
Globally, the reported prevalence of NAFLD varies from 11-46% between different populations, 
but in general it is highest in populations with a high pre-existing prevalence of type 2 diabetes 
[6] and obesity [7]. The prevalence of NAFLD increases with age [8], and most, though not all 
studies report that NAFLD is more prevalent in males [9]. The most common causes of death in 




the past several decades, the amount of people affected with diabetes has doubled globally, 
making it one of the cardinal public health challenges [11]. Over 11 years of follow-up, 
individuals with NAFLD are more likely to develop diabetes and the metabolic syndrome when 
compared with matched controls [12]. The occurrence of glycogen hepatopathy is associated 
with liver abnormalities in type 1 diabetes mellitus (T1DM) [12]. Despite the association 
between NAFLD and obesity, the two conditions do not necessarily coexist and it is there 
possible that the presence of NAFLD may help to distinguish between metabolically healthy and 
unhealthy obese individuals.  
 
Associations 
Although it is rarely implicated in the progression to chronic liver disease, simple hepatic 
steatosis without significant hepatic inflammation or scarring remains a health concern, owing to 
its strong associations with the metabolic syndrome [13], type 2 diabetes [6], insulin resistance 
[14], dyslipidemia [6], obesity [15] and increased mortality [16]. In a longitudinal study 
conducted in the Pima Indian population over 7 years of follow-up, serum alanine 
aminotransferase (ALT) was a significant predictor of T2DM with the association remaining 
significant after adjusting for percentage of body fat and direct measures of insulin sensitivity 
and secretion [17].  
 
Treatment of NAFLD with lifestyle interventions may provide prognostic benefit, and hence 
stratification of a patient’s individual risk of cardiovascular disease or progressive liver disease is 
of key importance for developing and implementing therapy. This process is complicated by a 




biomarker panels to cardiovascular endpoints, direct associations between NAFLD and 
cardiovascular disease, and the effectiveness of interventions aimed at reducing liver fat in 
mitigating cardiovascular risk. 
 
Screening and diagnosis of NAFLD 
Despite the strong associations between the two conditions, current guidelines provide 
conflicting recommendations as to whether patients with T2DM should be screened for NAFLD 
[18]. A high prevalence of NAFLD and/or advanced fibrosis has been found in patients with 
T2DM  [18], and hence the data support screening for NAFLD and/or advanced fibrosis with 
biomarkers, such as Fibro Test (FT) in this population. Evidence-based data suggest that 
biomarkers can be used as alternatives to liver biopsy for the first line assessment of fibrosis 
stage [19].  
 
The diagnosis and risk stratification of NAFLD both pose significant technical challenges. Liver 
biopsy has traditionally been considered the gold standard for the detection of features 
differentiating NASH from simple steatosis [20], but it has significant drawbacks including 
sampling error of an often patchy condition, leading to under- or over-representation in the 
histopathological specimen. Analysis of paired percutaneous liver biopsies show good agreement 
for the degree of steatosis, but show much poorer agreement for features of steatohepatitis or 
fibrosis, further indicating that liver biopsy may significantly underestimate the severity of 
patchily-distributed disease [21]. Liver biopsy and imaging techniques may be time-consuming 
and expensive and require a high level operator skill; consequently there has been considerable 






Single markers provide poor sensitivity and specificity for NASH, and consequently panels of 
multiple biomarkers have been developed to estimate an individual patient’s risk of simple 
hepatic steatosis or NASH. The Fatty Liver Index [22] (Equation 1), the lipid accumulation 
product (LAP) [23] (Equation 2) and the Liver Fat Score [24] (Equation 3) aim to identify 
increased risk of liver steatosis, while the NAFLD Fibrosis Score [25] (Equation 4) was designed 
to enable discrimination of patients with advanced fibrosis or cirrhosis from those with mild or 
no fibrosis. The Enhanced Liver Fibrosis (ELF), using a panel of nine biomarkers for liver 
fibrosis, initially designed to stage fibrosis, and is claimed to predict clinical outcomes of liver 
disease [26].  The HAIR score incorporates arterial hypertension, ALT and insulin resistance 
index to distinguish NASH from NAFLD [27] (Equation 5). As diabetes is associated with more 
severe forms of NAFLD, and the condition has often progressed silently to liver fibrosis, this is 
particularly important when coexisting diabetes is present. Identification of simple, inexpensive 
biomarkers would aid in predictable and reliable estimates of prevalence of NAFLD worldwide 
in people with diabetes and would provide a diagnostic tool for the monitoring of responses to 
therapeutic interventions [28]. While biomarker panels are reported to provide good sensitivity 
and specificity, their performance in further validation studies is limited and the initially-
published cut-off values do not reliably produce the best discrimination in other study 






Imaging techniques offer a more direct and potentially more reliable measurement of both liver 
fat content and fibrosis stage. Many of these techniques can differentiate between mild and 
severe disease, but fewer can accurately quantify levels of fat infiltration, or distinguish between 
degrees of mild and moderate fibrosis. While standard ultrasound provides sensitivity of 89% 
and specificity of 93% for the detection of hepatic steatosis [32], it provides limited 
quantification of liver fat content and cannot reliably detect mild fibrosis [33]. Moreover, 
ultrasound does not reliably detect hepatic fat content of less than 20% [34] and has limited 
sensitivity in individuals with body mass index (BMI) of greater than 40 kg/m² for reasons of 
technical visibility [35]. Ultrasound-based transient elastography, performed either separately or 
during ultrasound examination, can distinguish mild or absent fibrosis from severe fibrosis or 
cirrhosis, although the technique has several significant confounders and it is challenging to 
perform in people with BMI > 30 kg/m² [36]. ¹H-magnetic resonance spectroscopy (H-MRS) 
assessment of triglyceride content is widely considered to be a 'non-invasive gold standard' and 
has seen a huge increase in its application in recent years, although it is more common in a 
research contexts, rather than a clinical environment [37]. More recently the use of a 
combination of sequences based on T1 and T2* mapping to predict liver inflammation, iron 
accumulation and fibrosis (the “LIF” score) has been described [38]. 
 
Association with the metabolic syndrome 
NAFLD is now considered by many researchers to be the hepatic manifestation of the metabolic 
syndrome, rather than a primary liver disease [39]. The majorities (60.5%) of patients with 
NAFLD meet the National Cholesterol Education Program Adult Treatment Panel-III criteria for 




syndrome, such as increased abdominal obesity, are associated with steatosis [41]. Similarly, a 
high prevalence of NAFLD is reported in women diagnosed with polycystic ovarian syndrome 
[42] and in those with gestational diabetes [43], both conditions strongly associated with insulin 
resistance. 
Insulin resistance provides a plausible link between the pathogenesis of the metabolic syndrome 
and NAFLD. Adipose tissue insulin resistance increases influx of free fatty acids into the liver 
and systemic hyperinsulinaemia increases hepatic lipogenesis [44], whereas peripheral insulin 
resistance contributes to hypertriglyceridemia and intrahepatic fat accumulation [45]. Elevation 
of serum alanine aminotransferase (ALT) and an increased serum ALT, compared to the serum 
aspartate aminotransferase (AST) level – the ALT:AST ratio is associated with reduced insulin 
sensitivity and increased incidence of the metabolic syndrome [46]. There is increasing 
recognition that liver fat is more closely related to metabolic complications of obesity, such as 
insulin resistance and systemic inflammation than visceral fat, and that it is these metabolic 
alterations which underlie the myocardial systolic and diastolic dysfunction, which is notably 
absent in people with “metabolically healthy” obesity [13]. Since the metabolic syndrome is 
essentially a constellation of cardiovascular disease risk factors linked to insulin resistance [47], 
the question arises as to whether NALFD directly contributes to the pathogenesis of 
cardiovascular disease.  
 
Associations with cardiovascular risk factors 
In 40 individuals with ultrasound-diagnosed NAFLD matched for sex and age, but not diabetes 
status, to healthy individuals, NAFLD was associated with significant increases in carotid 




plaque (20 vs. 10, p=0.021) detected by ultrasound of the carotid artery [48].  In a group of 4,222 
randomly-selected people of German descent, the prevalence of carotid atherosclerotic plaque 
disease was significantly higher in individuals with ultrasound diagnosis of hepatic steatosis 
(29.9%), when corrected for age, sex, diabetes status, hypertension, BMI, total cholesterol:HDL 
cholesterol ratio, and plasma fibrinogen, although no significant difference in carotid intima-
media thickness was found when adjusted for the same covariates [49]. NAFLD was found to be 
associated with a reduction in the vasodilatory response to ischemia of the brachial artery, a 
marker of endothelial dysfunction, and a moderate increase in Framingham cardiovascular risk 
score [50]. It should perhaps be noted that the Framingham risk score does not take account of 
visceral or liver fat and that, to a large extent, the data collected in the Framingham study 
predates the NAFLD epidemic. The presence of NAFLD was associated with an increase in 
coronary artery calcification score in 1,854 South Korean individuals without previously 
identified liver or coronary artery disease, when adjusted for the degree of visceral adiposity in 
multivariate analysis [51]. In another cohort of 10,153 middle-aged South Korean adults, who 
underwent liver ultrasound and cardiac computed tomography as part of occupational screening, 
NAFLD was associated with increased coronary artery calcium score independent of HOMA-IR, 
features of the metabolic syndrome, coexisting cardiovascular risk factors, and previous evidence 
of cardiovascular disease [52]. Sixty patients who underwent liver transplantation for NASH-
related or cryptogenic cirrhosis had significantly higher prevalence of obesity, hypertension, 
diabetes mellitus, the metabolic syndrome and coronary artery disease than an age- and sex-
matched control group of 60 patients with cirrhosis due to any other etiology [53]. Among 161 
individuals referred for liver evaluation at a hospital in Ankara, the degree of ultrasound-graded 




with brachial flow-mediated dilatation, although multicollinearity introduced into the linear 
regression analysis by the inclusion of metabolic syndrome as diagnosed by NCEP ATP-III 
criteria along with the individual NCEP ATP-III components as covariates is likely to have 
significantly biased the outcomes of these analyses [54]. However, there is a lack of overall 
consensus as to whether or not NAFLD is associated with increased cardiovascular risk 
independently of other established risk factors [50]-[53]. 
 
More recently, associations have been demonstrated between non-alcoholic fatty liver, 
steatohepatitis and serum markers associated with cardiovascular endpoints. Plasminogen 
activator inhibitor-1 (PAI-1), which inhibits fibrinolysis, is associated with an increased 
incidence of first myocardial infarction [55]. In a retrospective, cross-sectional analysis of 44 
children undergoing liver biopsy, increased plasma PAI-1 was associated with both higher 
grades of steatosis and the presence of steatohepatitis, and with total and non-HDL cholesterol 
and estimated insulin resistance, after adjustment for age, sex and ethnicity [56]. Higher plasma 
levels of adiponectin, an adipokine hormone, which is negatively associated with obesity and 
insulin resistance, independently predict a reduced risk of coronary artery disease in men with 
type 2 diabetes [57].   
 
Associations with cardiovascular outcomes 
A meta-analysis of randomized controlled trials and cohort studies indicates that the risk of 
incident cardiovascular disease increases in the presence of the metabolic syndrome [58], but 
evidence for an association between NAFLD and cardiovascular endpoints is more limited. In 




diagnosed using ultrasound was significantly associated with a composite endpoint of non-fatal 
myocardial infarction, coronary revascularization, non-fatal ischemic stroke and cardiovascular 
death in multivariate regression, when adjusted for age, sex, smoking status, duration of diabetes, 
HbA1c, LDL cholesterol and the use of hypoglycemic, antihypertensive, lipid-lowering and 
antiplatelet drugs [59]. Data from the NHANES III cohort demonstrated increased overall 
mortality in individuals with NAFLD after a median of 8.7 years follow-up, with the three most 
common causes of death being cardiovascular disease, malignancy and chronic liver disease 
[60]. A retrospective review of 286 European patients with type 1 diabetes, of whom 150 met 
ultrasound criteria for any grade of NAFLD, found an increased hazard ratio for a composite 
endpoint of cerebrovascular, coronary artery or peripheral vascular disease of 6.73 (95% CI 1.2 - 
38.1, p = 0.031) after a mean of 5.3 years’ follow-up, adjusted for age, sex, body mass index, 
smoking, diabetes duration, HbA1c, dyslipidemia, hypertension, chronic kidney disease, prior 
ischemic heart disease and serum gamma-glutamyltransferase [47]. In a cohort of 317 adults 
undergoing elective coronary artery angiography, ultrasound-detected fatty liver disease was a 
significant predictor of >30% stenosis of at least one coronary artery in multivariate regression 
when corrected for sex, waist-hip ratio, body mass index, diabetes mellitus, hypertension, serum 
triglycerides and LDL [61]. 
 
In a prospective study of 1637 Japanese individuals attending a health screening service, 12 of 
231 individuals (5.1%) with ultrasound-diagnosed NAFLD reported a new cardiovascular event 
(5 coronary artery disease, 6 ischemic stroke, 1 hemorrhagic stroke), compared with 10 of 990 
(1.0%) individuals without NAFLD, during a five year follow-up period; NAFLD remained an 




In a longitudinal cohort study, cardiovascular events occurred in 17 of 91 patients (19%) with 
ultrasound-diagnosed NAFLD and 18 of 182 age-matched controls; NAFLD was associated with 
greater carotid intima-media thickness (CIMT) at enrolment, but a smaller increase in CIMT 
during follow-up [63]. A similar association between NALFD and increased CIMT in younger 
(age <45 years), but not older people, has been reported in a cross-sectional study of a cohort of 






Management of NAFLD 
To date there are no licensed treatments for NAFLD and lifestyle modification is currently 
considered to be the only effective intervention. However, several drugs licensed for other 
indications are now being tested in NAFLD [28]. The severity of type 2 diabetes and liver 
disease influence the therapy. Management of type 2 diabetes in patients with liver diseases is, 
for the most part, the same as without liver disease. First-line therapy with metformin is 
appropriate in most patients, but not recommended in patients with advanced hepatic disease, 
because of a perceived increased risk of lactic acidosis. Recent trials have shown some benefit in 
patients with fatty liver and type 2 diabetes [18]. Decreased alcohol intake should be 
recommended [28]. A meta-analysis of trials on diet and exercise showed that performing 
exercise 3 times a week for 4 weeks was associated with a reduction in intrahepatic triglyceride 




both diet and exercise produced a 10% reduction in weight over 6 months, resulting in 
improvement of histological findings and reduction of steatosis on repeat liver biopsy [65]. The 
UK National Health Service advises weight loss with a BMI target of 18.5-24.9 [66]. Both 
resistance training and aerobic training improved MRI-assessed hepatic fat content and insulin 
resistance in sedentary people with type 2 diabetes [67]. A meta-analysis of nine studies of 
dietary supplementation of omega-3 polyunsaturated fatty acid indicates a potential for reduction 
of liver fat, as assessed by ultrasound or magnetic resonance spectroscopy, but no benefit in 
terms of normalization of liver enzymes [68]. 
The evidence that treatment of NAFLD can reduce cardiovascular risk is modest. A 16-week 
moderate-intensity supervised exercise program was associated with significant reductions in 
liver fat and serum transaminases, along with increased cardiorespiratory fitness and flow-
mediated brachial artery dilatation, in ten obese Caucasian individuals with MRI-measured liver 
fat between 5.5% and 80%, but these changes were not sustained 12 months, following the 
cessation of the intervention [69]. 
 
Conclusions 
Non-alcoholic fatty liver disease is both highly prevalent and increasing in prevalence 
worldwide. Biomarker panels offer reasonable sensitivity and specificity for the diagnosis of 
NAFLD, but there is a lack of evidence for their utility outside of the initial screening process. 
No treatment has been demonstrated to directly influence progression to steatohepatitis. 
Evidence for a direct effect of NAFLD on cardiovascular risk and outcomes over and above its 
association with the metabolic syndrome is very limited. Further elucidation of this potential link 




fibrosis, and hard cardiovascular outcomes instead of estimated cardiovascular risk as study 
endpoints. At present, careful modification of acknowledged risk factors for arterial disease 
according to generally accepted guidelines is recommended.  
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Performance of clinical scores 
Score Endpoint Cut Performance Source 
FLI Rule out FL (US) ≤ 30 Se 87%, Sp 64%, AR 0.85 (0.81-0.88) Bedogni 2006[22]  
  Rule in FL (US) ≥ 60 Se 61%, Sp 86%, AR 0.85 (0.81-0.88) Bedogni 2006[22]   
  Steatosis > 5% 
(biopsy) 
> 60 PP 99%, NP 15%, AR 0.83 (0.72-0.91) Fedchuk 2014[70] 
  Steatosis > 33% 
(biopsy) 
> 60 PP 71%, NP 56%, AR 0.65 (0.59-0.71) Fedchuk 2014 [70] 
  Steatosis (US) ≥ 60  PP 72.2%, NP 81.5% Zelber-Sagi 2013[31]  
  HRI ≥ 1.5 ≥ 60 PP 57.0%, NP 86.1% Zelber-Sagi 2013[31] 
  HCL > 5.56 % 
(MRS) 
>29.2 PP 33%, NP 94%, AR 0.72 (0.59-0.85) Kahl 2014 [71] 
  USS steatosis grade 
≥ 2 
>48 PP 74.4%, NP 88.7%, AR 0.91 (0.87-0.95) Carvalhana 2014 [72] 
LAP Steatosis (US) N/A AR 0.79 (0.76-0.83) Bedogni 2010 [23] 
  Severe steatosis (US) N/A AR 0.79 (0.76-0.83) Bedogni 2010[23]  
LFS Liver fat ≥ 55.6 mg 




-0.640 Se 86%, Sp 71%, AR 0.86 (0.83-0.89) Kotronen 2009 [24]   
  Steatosis > 5% 
(biopsy) 
> 0.16 PP 99%, NP 16%, AR 0.80 (0.69-0.88) Fedchuck 2014[70]  
  Steatosis > 33% 
(biopsy) 
> 0.16 PP 71%, NP 67%, AR 0.72 (0.66-0.77) Fedchuck 2014 [70] 
  HCL > 5.56% 
(MRS) 
-1.02 PP 56%, NP 55%, AR 0.70 (0.53-0.87) Kahl 2014[71]   
N-FS Advanced fibrosis 
(biopsy) 
0.676 PP 90%, NP 82%, AR 0.82 Angulo 2007[25]  
  Advanced fibrosis 
(biopsy) 
-1.455 PP 30%, NP 92%, AR 0.81 (0.71-0.91) McPherson 2010[73] 
  Advanced fibrosis 
(biopsy) 
0.676 PP 79%, NP 86%, AR 0.81 (0.71-0.91) McPherson 2010[73]  
  Severe fibrosis 
(biopsy) 
0.676 PP 100%, NP 81.3%, AR 0.68 (0.57-0.78) Ruffillo 2011[30] 
  Fibroscan stage ≥ F2   Se 52.3%, Sp 88.6%, AR 0.67 (0.61-0.73) Aykut 2014[29] 




Table 1 Reported performance of clinical scores for diagnosis of liver steatosis, non-alcoholic 
steatohepatitis or fibrosis. FLI = Fatty Liver Index, LAP = Lipid Accumulation Product, LFS = 
Liver Fat Score, NAFLD = Non-Alcoholic Fatty Liver Disease, NASH = Non-Alcoholic 
Steatohepatitis, N-FS = NAFLD Fibrosis Score, HAIR = Hypertension, ALT, Insulin Resistance 
, FL = Fatty Liver, US = Ultrasound, HRI = Hepatorenal Ultrasound Index (ratio of US 
brightness of liver to renal cortex in same sonographic plane), HCL = Hepatocellular Lipid, Se = 
Sensitivity, Sp = Specificity, AR = Area Under the Receiver Operator Curve, PP = Positive 





Clinical risk scoring; 
 
     
                                                       
                                                         
      
 
Equation 1: Fatty Liver Index. TG = Triglycerides (mg/dL), BMI = Body Mass Index (kg/m2), GGT = 
Gamma-Glutamyl Transferase (U/L), WC = Waist Circumference (cm) [24]. 
 
                              
 
Equation 2: The Lipid Accumulation Product. WC = Waist Circumference (cm), TG = Triglycerides 
(mmol/L) [25]. 
 
                                                            
 
Equation 3: The Liver Fat Score. MetS = presence of the Metabolic Syndrome (yes = 1, no = 0), T2DM 
= presence of Type 2 Diabetes Mellitus (yes = 1, no = 0), Ins = serum Insulin (mU/L), AST = Aspartate 





                                            
   
   
                    
 
Equation 4: The NAFLD Fibrosis Score. Age = age in years, BMI = Body Mass Index (kg/m2), HG = 
Impaired Fasting Glucose, Impaired Glucose Tolerance or Diabetes Mellitus (yes = 1, no = 0), AST = 
Aspartate aminotransferase (U/L), ALT = Alanine aminotransferase (U/L), Plt = platelets (1000/µcL), 
Alb = serum Albumin (g/dL). [27] 
 
                                   
 
Equation 5: The HAIR score. Hypertension = previously diagnosed hypertension, IRI = Insulin 
Resistance Index (log (Fasting Glucose (mg/dL) + log (Fasting Insulin (mIU/L)), ALT = Alanine 
aminotransferase (U/L). A HAIR of ≥2 is reported to provide sensitivity of 80% and specificity of 89% 
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